<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191213</url>
  </required_header>
  <id_info>
    <org_study_id>GA&amp; Sickle among children</org_study_id>
    <nct_id>NCT04191213</nct_id>
  </id_info>
  <brief_title>Gum Arabic as Anti-oxidant, Anti-inflammatory and Fetal Hemoglobin Inducing Agent in Sickle Cell Anemia Patients</brief_title>
  <acronym>GA&amp;SCA</acronym>
  <official_title>Efficacy of Gum Arabic as Anti-oxidant, Anti-inflammatory and Fetal Hemoglobin Inducing Agent in Sickle Cell Anemia Patients : A Randomized, Double-blind, Two-armed Parallel-group, Placebo-controlled Phase II/III Study - Khartoum, Sudan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Al-Neelain University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Khartoum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Al-Neelain University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the efficacy of Gum Arabic as an anti-oxidant, anti-inflammatory and Fetal
      Hemoglobin-inducing agent among Sickle Cell Disease children. Half of participants will
      receive Gum Arabic and the other half will receive placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polymerized hemoglobin is injurious to the red cell membrane, resulting in oxidative damage
      in sickle cell disease . Fetal hemoglobin is protective against sickling and its decrease is
      associated with vaso-occlusive crisis . Gum Arabic is soluble fibers with prebiotic
      properties. It increased the level of serum butyrate which is short chain fatty acid. The
      latter proved to serve as fetal hemoglobin inducing agent both in vivo and in vitro study.
      And also has strong anti-inflammatory properties. So our aim to test whether oral digestion
      of Gum Arabic will induce fetal hemoglobin among sickle cell pediatric patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 15, 2020</start_date>
  <completion_date type="Anticipated">July 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The intervention group will receive Gum Arabic. And The placebo group will receive pectin</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants, care providers, Investigator and outcome assessor will be masked regarding the type of intervention each group will receive</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Fetal hemoglobin level after 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measure increase from the baseline values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total anti oxidant capacity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measure increase from the baseline values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti inflammatory marker C reactive Protein</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measure decrease from the baseline values</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sickle Cell Anemia in Children</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose for participants above 5 years of age and 15-grams-dose for participants below 5 years of age for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will be provided with pectin powder provided as one-gram-dose for children below 5 years of age &amp; two-gram-dose for children above 5 years of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Acacia Senegal extract</intervention_name>
    <description>Oral Digestion of Gum Arabic to be consumed early morning in daily basis for 12 weeks</description>
    <arm_group_label>Intervention Group</arm_group_label>
    <other_name>(Gum Arabic)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pectin</intervention_name>
    <description>Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Homozygous for Sickle Cell Disease (SS) as documented by Haemoglobin electrophoresis.

        Subjects whom medications and dosages had been stable for 2 weeks before study entry.

        Subjects who have not received blood transfusion or had acute episode related to sickle
        cell disease in the last two weeks before the start of intervention.

        Exclusion Criteria:

          -  Patients with history of Gum Arabic allergy. Patients who have ischemic heart disease,
             liver dysfunction or hepatitis. Pregnant female patients who plan to conceive in the
             next 4 months and fertile female patients who are not using an effective contraception
             method.

        Patients who are currently using Gum Arabic. Patients who are on steroids or chemotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Imad M Fdl-Elmula, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alneelain University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dalya MM Abdelmaged, MBBS</last_name>
    <phone>00249126831595</phone>
    <email>dalya.alfeel@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lamis AA KAddam, PhD</last_name>
    <phone>+249912979736</phone>
    <email>lamiskaddam@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Military Hospital</name>
      <address>
        <city>Omdurman</city>
        <state>Khartoum</state>
        <zip>1113</zip>
        <country>Sudan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haydar A Abdelrazig, MD</last_name>
      <phone>249123431031</phone>
      <email>habdelhakam1@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Haydar A Abdelrazig, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dalya MM Abdelmaged, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lamis AA Kaddam, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sudan</country>
  </location_countries>
  <reference>
    <citation>Kaddam L, FdleAlmula I, Eisawi OA, Abdelrazig HA, Elnimeiri M, Lang F, Saeed AM. Gum Arabic as fetal hemoglobin inducing agent in sickle cell anemia; in vivo study. BMC Hematol. 2015 Dec 29;15:19. doi: 10.1186/s12878-015-0040-6. eCollection 2015.</citation>
    <PMID>26719803</PMID>
  </reference>
  <reference>
    <citation>Kaddam L, Fadl-Elmula I, Eisawi OA, Abdelrazig HA, Salih MA, Lang F, Saeed AM. Gum Arabic as novel anti-oxidant agent in sickle cell anemia, phase II trial. BMC Hematol. 2017 Mar 16;17:4. doi: 10.1186/s12878-017-0075-y. eCollection 2017.</citation>
    <PMID>28331623</PMID>
  </reference>
  <reference>
    <citation>Kamal E, Kaddam LA, Dahawi M, Osman M, Salih MA, Alagib A, Saeed A. Gum Arabic Fibers Decreased Inflammatory Markers and Disease Severity Score among Rheumatoid Arthritis Patients, Phase II Trial. Int J Rheumatol. 2018 Jul 5;2018:4197537. doi: 10.1155/2018/4197537. eCollection 2018.</citation>
    <PMID>30112005</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>January 26, 2020</last_update_submitted>
  <last_update_submitted_qc>January 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Al-Neelain University</investigator_affiliation>
    <investigator_full_name>Lamis Kaddam</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>sickle cell anemia</keyword>
  <keyword>Gum Arabic</keyword>
  <keyword>Fetal Hemoglobin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Share patients data without personal data and without breaching confidentiality</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

